Data Visualization•7 min read•Updated 2026-04-03

    GLP-1 Side Effect Comparison Chart: Semaglutide vs Tirzepatide vs Retatrutide

    Visual comparison of side effect rates across all GLP-1 medications. Data-driven chart showing nausea, vomiting, diarrhea, and other side effects by medication and dose.

    More on Data Visualization

    View all Data Visualization articles

    Weight Loss Chart

    Results data

    Managing Side Effects

    Side effect tips

    Data Summary

    All GLP-1 medications share similar GI side effects that are typically mild and transient. Only 4-7% of patients discontinue treatment. Proper dose titration significantly reduces side effect severity.

    Side Effect Rates by Medication

    Side EffectSemaglutideTirzepatideRetatrutideTypical Severity
    Nausea44%25-33%33%Mild-Moderate
    Diarrhea30%21-25%22%Mild
    Vomiting24%9-13%17%Mild-Moderate
    Constipation24%14-17%18%Mild
    Abdominal Pain20%8-14%12%Mild
    Headache14%8-10%10%Mild
    Fatigue11%5-7%8%Mild
    Injection Site Reaction3%3-5%5%Mild

    Data from highest approved/studied doses. Rates at lower starting doses are significantly lower. Sources: STEP, SURMOUNT, and Phase 2 retatrutide trials.

    Understanding the Data

    Good News

    • Most side effects resolve within 4-8 weeks
    • Slow titration reduces severity by 40-60%
    • Serious side effects are rare (under 1%)
    • 93-96% of patients continue treatment

    Management Strategies

    • Eat small, frequent meals to reduce nausea
    • Stay well hydrated (80+ oz water daily)
    • Take fiber supplements for constipation
    • Contact your provider if side effects persist beyond 2 weeks

    Medical Disclaimer: This data represents clinical trial averages. Individual experiences vary. Report severe or persistent side effects to your healthcare provider immediately.

    Frequently Asked Questions

    Which GLP-1 has the fewest side effects?

    At equivalent weight-loss-producing doses, side effect profiles are similar across GLP-1 medications. Tirzepatide may have slightly lower nausea rates than semaglutide at comparable efficacy. Most side effects are GI-related and diminish over 4-8 weeks as the body adjusts.

    How common is nausea on GLP-1 medications?

    Nausea occurs in approximately 40-44% of semaglutide patients and 25-33% of tirzepatide patients during dose titration. It is usually mild to moderate and transient, resolving within the first month at each dose level. Only 4-7% of patients discontinue due to side effects.

    Do side effects get worse at higher doses?

    Side effects can temporarily increase with each dose escalation. Slow titration (staying at each dose for 4+ weeks) significantly reduces side effect severity. Most patients tolerate higher doses well after the initial adjustment period.

    What percentage of patients stop treatment due to side effects?

    Across clinical trials, 4-7% of patients discontinue GLP-1 medications due to adverse events. This is remarkably low given the significant weight loss benefits. Proper titration and side effect management reduce discontinuation rates further.

    Expert-Guided GLP-1 Treatment

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo with side effect management support.

    View Treatment Options

    What should patients know about GLP-1 side effects?

    Peer-reviewed / regulatory evidence: In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. (Source: STEP 1, NEJM 2021). Trimi's clinical-review process — coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network — addresses GLP-1 side effects as part of the individualized patient-care plan. Compounded medications are dispensed by 503A community sterile compounding pharmacies (VialsRx, GreenwichRx). This is general information based on the cited sources, not medical advice.

    In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. — STEP 1, NEJM 2021
    In SURMOUNT-1, gastrointestinal adverse events occurred in approximately 81% of tirzepatide 15 mg participants vs 53% of placebo participants over 72 weeks; most resolved with continued therapy and dose adjustment. — SURMOUNT-1, NEJM 2022

    Key Takeaways

    • In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. (Source: STEP 1, NEJM 2021)
    • In SURMOUNT-1, gastrointestinal adverse events occurred in approximately 81% of tirzepatide 15 mg participants vs 53% of placebo participants over 72 weeks; most resolved with continued therapy and dose adjustment. (Source: SURMOUNT-1, NEJM 2022)
    • Most GLP-1 adverse events are gastrointestinal (nausea, vomiting, diarrhea, constipation), mild-to-moderate in severity, and concentrated during dose-escalation weeks. Severe or persistent symptoms should be discussed with the prescribing clinician promptly.
    • GLP-1 receptor agonists require a prescription. Eligibility is determined by a licensed clinician based on BMI, weight-related comorbidities, and screening for contraindications (medullary thyroid carcinoma history, MEN 2, pancreatitis history, severe GI / renal disease, pregnancy, breastfeeding).
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: December 9, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    — u/CSWB101Reddit (r/TirzepatideRX)
    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    — Amy KeithFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. U.S. Food and Drug Administration (2024). Wegovy (semaglutide) Prescribing Information — Adverse Reactions section. FDA.Read Study
    2. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information — Adverse Reactions section. FDA.Read Study
    3. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Safety endpoints. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183

    Was this article helpful?

    Keep Reading

    Data Visualization

    GLP-1 Weight Loss Results by Medication: Visual Data Comparison

    Interactive visual comparison of weight loss results across semaglutide, tirzepatide, and retatrutide from clinical trials and real-world data.

    10 minRead More
    Side Effects & Safety

    Semaglutide vs Tirzepatide Nausea

    Semaglutide vs Tirzepatide: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 data plus how each stacks against Trimi.

    8 minRead More
    Comparisons

    Semaglutide vs Tirzepatide vs Retatrutide: 2026 Side Effect Chart

    Verified side-effect rates: semaglutide vs tirzepatide vs retatrutide. Nausea, GI tolerance, and discontinuation rates from FDA trials, plus the safest starting dose for each.

    10 minRead More
    Comparisons

    Semaglutide vs Tirzepatide vs Phentermine vs Metformin for Weight Loss

    Four-way comparison of the most prescribed weight loss medications in 2026. Compare efficacy, side effects, cost, duration of use, and who each drug is best for.

    13 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started